Pfizer's Abrysvo and GSK's Arexvy both received FDA-approval b in 2024 to include immunization of adults aged 50 to 59 years at increased risk for RSV disease.

A new global study led by GlaxoSmithKline has found that a single dose of the RSV vaccine Arexvy (RSVPreF3 OA) offers strong ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

A key group of government advisers voted to expand the use of vaccines for a common respiratory illness, providing a boost to ...

The U.S. Centers for Disease Control and Prevention's panel of outside experts on Wednesday recommended the use of ...

The Advisory Committee on Immunization Practices voted Wednesday to recommend lowering the age at which adults can get a ...

New studies on respiratory syncytial virus (RSV) in both adults and young children show that infections are linked to a ...

The CDC's Advisory Committee on Immunization Practices (ACIP) voted 14-0, with one abstention, on Wednesday to recommend that ...

A federal panel of experts on Wednesday recommended an expansion of RSV vaccinations for adults and a new combination shot as ...

On Wednesday, the Advisory Committee on Immunization Practices (ACIP) voted to expand its recommendation for the use of ...

Pfizer Inc. (NYSE: PFE) announced today that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee ...

A single dose of the RSVPreF3 OA vaccine offers strong protection against RSV-related lower respiratory tract disease in ...